Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations
T cell immunity affects the time required to acquire resistance after EGFR-TKI treatment. Pretreatment CXCR3<sup>+</sup>CCR4<sup>-</sup>CCR6<sup>+</sup>CD4<sup>+</sup> T cell cluster was significantly associated with PFS after osimertinib treatment, likely predicting osimertinib efficacy. Antitumor T cell immunity may be crucial for preventing the acquisition of EGFR-TKI resistance.
Authors
- Hiroshi Kagamu (ORCID: https://orcid.org/0000-0003-4523-8517)
- Ayako Shiono (ORCID: https://orcid.org/0000-0001-6546-3864)
- Kunihiko Kobayashi (ORCID: https://orcid.org/0000-0002-6468-9068)
- Satoshi Yamasaki (ORCID: https://orcid.org/0000-0003-4722-9315)
- Kyoichi Kaira (ORCID: https://orcid.org/0000-0001-5548-7686)
- Hisao Imai (ORCID: https://orcid.org/0000-0003-3097-4255)
- Atsuto Mouri
- Ou Yamaguchi (ORCID: https://orcid.org/0000-0001-7194-6459)
- Fuyumi Nishihara (ORCID: https://orcid.org/0000-0002-3999-6752)
- Kosuke Hashimoto (ORCID: https://orcid.org/0000-0001-7627-7901)
- Yu Miura (ORCID: https://orcid.org/0000-0002-2752-5873)
Institutions
- Saitama Medical University (JP)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1007/s00262-025-04113-0
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00